Evidence-Based Evaluation and Selection of Essential Medicine for Pilot Township Health Centers Located in Eastern, Central and Western China, Part II: Study on Evaluation Standards, Methods and Processes_Chinese Journal of Evidence-Based Medicine

Authors：

LI Honghao ,  LI Youping , WANG Li , YANG Xiaoyan

Chinese Evidence-Based Medicine Center, West China Hospital, Chengdu 610041, China;

Corresponding author：

LI Youping, Email: yzmylab@hotmail.com

Keywords：

Township health center; Essential medicine; Evidence-based evaluation and selection; Standard and method of evaluation; GRADE

DOI：

10.7507/1672-2531.20120056

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective　 To establish standards, methods and processes for evidence-based evaluation and selection of essential medicine that meet the needs of the 8 pilot township health centers in China.
Methods 　A descriptive analysis was conducted to compare the similarities/differences and the advantages/disadvantages of the standards, methods and processes between the World Health Organization (WHO) essential medicines evaluation and selection, and the GRADE evidence quality and recommend intensity. In combination with the former outcomes of this series of study, the standards, methods and processes of evidence-based evaluation and selection of essential medicines in the domestic pilot township health centers were optimized, restructured and improved. Softwares such as GRADEprofiler were used to assess the quality of evidence.
Results　 a) Localized standards, methods and processes for evidence-based evaluation and selection of essential medicine were established, and the evaluation tool was ascertained; and b) Disease and drug names, guidelines and searching processes for evaluation and selection of essential medicine were developed with standardized, systematic and transparent approaches.
Conclusion　 a) Standards, methods and processes for searching, evaluating and recommending the best evidence are preliminarily established, through comparative analysis on the effectiveness, safety, cost-effectiveness and applicability of the candidate medicines for diagnosing, treating and preventing diseases in township health centers in China; b) Following the principle of “utilizing the best existing evidences and developing the urgently-needed but lacking evidence”, a good exploration was done for the localization, standardization and transparency of the standards, methods and processes of evidence-based evaluation and selection of essential medicine for pilot township health centers.

Citation： LI Honghao,LI Youping,WANG Li,YANG Xiaoyan. Evidence-Based Evaluation and Selection of Essential Medicine for Pilot Township Health Centers Located in Eastern, Central and Western China, Part II: Study on Evaluation Standards, Methods and Processes. Chinese Journal of Evidence-Based Medicine, 2012, 12(3): 347-356. doi: 10.7507/1672-2531.20120056 Copy

1.	http: //www.who.int/selection_medicines/committees/expert/17/application/Amantadine_Rimantadine.pdf. 2011.10.
2.	12 Guyatt GH, Oxman AD, Vist GE, et al , GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ , 2008. 336(7650): 924-926.
3.	www.cochrane-handbook.org.
4.	Secretariat of WHO EXECUTIVE BOARD. WHO medicines strategy: Revised procedure for updating WHO’s Model List of Essential Drugs (EB109/8). 109th Session. 7 December 2001: 7.
5.	王莉, 袁强, 成岚, 等. 我国基本药物目录遴选与评价方法的问题与反思. 中国药房, 2010, 21(16): 1453-1456.
6.	WHO.The selection and use of essential medicines. Report of the WHO Expert Committee, 2009. WHO Technical Report Series, 958: 8, 31.
7.	WHO. Proposal for the inclusion of Amantadine and Rimantadine in the World Health Organisation model list of essential medicines. WHO.2009, 5.
8.	杨悦, 何畔, 邹韵, 等. 推荐分级的评估、制定与评价方法以及WHO在基本药物遴选中的应用. 中国药房, 2011, 22(32): 2977-2981.
9.	李幼平, 王莉, 杨晓妍, 等. 我国基本药物目录制定及实施的循证思考. 中国循证医学杂志 2009, 9(11): 1131-1134.
10.	肖爱丽.《国家基本药物目录》遴选与调整的思考. 中国药房, 2010, 21(12): 1072.
11.	WHO. How to develop a National Essential Medicines List.who.2010, 11. http: //www.who.int/selection_medicines/committees/expert/18/How_to_developNEML_agenda_paper.pdf.2012.2.
12.	曾宪涛, 田国祥, 牛玉明, 等. GRADEprofiler软件的使用简介. 中国循证心血管医学杂志, 2011, 3(5): 390-392.
13.	曾宪涛, 冷卫东, 李胜, 等, 如何正确理解及使用GRADE系统. 中国循证医学杂志, 2011, 11(9): 985-990.
14.	刘为民, 刘保延, 何丽云, 等. 引入GRADE体系制定中医药国际标准的思考与实践探析. 亚太传统医药, 2011, 7(1): 1-5.
15.	GRADE指南: Ⅰ.导论——GRADE证据概要表和结果总结表. 中国循证医学杂志, 2011, 11(4): 437-445.
16.	Gordon H. Guyatt, Andrew D. Oxman, Regina Kunz, 等. GRADE指南: Ⅱ.构建问题、确定重要结果. 中国循证医学杂志, 2011, 11(4): 446-450.
17.	Howard Balshem, Mark Helfanda, Holger J. Schunemann, 等. GRADE指南: Ⅲ.证据质量分级. 中国循证医学杂志, 2011, 11(4): 451-455.
18.	Gordon H. Guyatt, Andrew D. Oxman, Gunn Vist, 等. GRADE指南: Ⅳ.证据质量分级——研究的局限性(偏倚风险). 中国循证医学杂志, 2011, 11(4): 456-463.
19.	Gordon H. Guyatt, Andrew D. Oxman, Victor Montori, 等. GRADE指南: Ⅴ.证据质量评价——发表偏倚. 中国循证医学杂志, 2011, 11(12): 1430-1434.
20.	Gordon Guyatt, Andrew D. Oxman, Regina Kunz, 等. GRADE指南: Ⅵ.证据质量评价——不精确性(随机误差). 中国循证医学杂志, 2011, 11(12): 1435-1443.
21.	Gordon H. Guyatt, Andrew D. Oxman, Regina Kunz, 等. GRADE指南: Ⅶ.证据质量评价——不一致性. 中国循证医学杂志, 2011, 11(12): 1444-1451.
22.	Gordon Guyatt, Andrew D. Oxman, Regina Kunz, 等. GRADE指南: Ⅷ.证据质量评价——间接性. 中国循证医学杂志, 2011, 11(12): 1452-1458.
23.	Gordon H. Guyatt, Andrew D. Oxman, Shahnaz Sultan, 等, GRADE指南: Ⅸ.证据质量升级. 中国循证医学杂志, 2011, 11(12): 1459-1463.
24.	Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from.
25.	Guyatt GH, Oxman AD, Kunz R, et al . GRADE guidelines: 2. Framing the question and deciding on important outcomes. Clin Epidemiol , 2011, 64(4): 395-400.
26.	Schünemann H, Bro?ek J, Oxman A, editors. GRADE handbook for Grading quality of evidence and strength of recommendation. 3.2 [updated March 2009]. Section 3.

1. http: //www.who.int/selection_medicines/committees/expert/17/application/Amantadine_Rimantadine.pdf. 2011.10.
2. 12 Guyatt GH, Oxman AD, Vist GE, et al , GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ , 2008. 336(7650): 924-926.
3. www.cochrane-handbook.org.
4. Secretariat of WHO EXECUTIVE BOARD. WHO medicines strategy: Revised procedure for updating WHO’s Model List of Essential Drugs (EB109/8). 109th Session. 7 December 2001: 7.
5. 王莉, 袁强, 成岚, 等. 我国基本药物目录遴选与评价方法的问题与反思. 中国药房, 2010, 21(16): 1453-1456.
6. WHO.The selection and use of essential medicines. Report of the WHO Expert Committee, 2009. WHO Technical Report Series, 958: 8, 31.
7. WHO. Proposal for the inclusion of Amantadine and Rimantadine in the World Health Organisation model list of essential medicines. WHO.2009, 5.
8. 杨悦, 何畔, 邹韵, 等. 推荐分级的评估、制定与评价方法以及WHO在基本药物遴选中的应用. 中国药房, 2011, 22(32): 2977-2981.
9. 李幼平, 王莉, 杨晓妍, 等. 我国基本药物目录制定及实施的循证思考. 中国循证医学杂志 2009, 9(11): 1131-1134.
10. 肖爱丽.《国家基本药物目录》遴选与调整的思考. 中国药房, 2010, 21(12): 1072.
11. WHO. How to develop a National Essential Medicines List.who.2010, 11. http: //www.who.int/selection_medicines/committees/expert/18/How_to_developNEML_agenda_paper.pdf.2012.2.
12. 曾宪涛, 田国祥, 牛玉明, 等. GRADEprofiler软件的使用简介. 中国循证心血管医学杂志, 2011, 3(5): 390-392.
13. 曾宪涛, 冷卫东, 李胜, 等, 如何正确理解及使用GRADE系统. 中国循证医学杂志, 2011, 11(9): 985-990.
14. 刘为民, 刘保延, 何丽云, 等. 引入GRADE体系制定中医药国际标准的思考与实践探析. 亚太传统医药, 2011, 7(1): 1-5.
15. GRADE指南: Ⅰ.导论——GRADE证据概要表和结果总结表. 中国循证医学杂志, 2011, 11(4): 437-445.
16. Gordon H. Guyatt, Andrew D. Oxman, Regina Kunz, 等. GRADE指南: Ⅱ.构建问题、确定重要结果. 中国循证医学杂志, 2011, 11(4): 446-450.
17. Howard Balshem, Mark Helfanda, Holger J. Schunemann, 等. GRADE指南: Ⅲ.证据质量分级. 中国循证医学杂志, 2011, 11(4): 451-455.
18. Gordon H. Guyatt, Andrew D. Oxman, Gunn Vist, 等. GRADE指南: Ⅳ.证据质量分级——研究的局限性(偏倚风险). 中国循证医学杂志, 2011, 11(4): 456-463.
19. Gordon H. Guyatt, Andrew D. Oxman, Victor Montori, 等. GRADE指南: Ⅴ.证据质量评价——发表偏倚. 中国循证医学杂志, 2011, 11(12): 1430-1434.
20. Gordon Guyatt, Andrew D. Oxman, Regina Kunz, 等. GRADE指南: Ⅵ.证据质量评价——不精确性(随机误差). 中国循证医学杂志, 2011, 11(12): 1435-1443.
21. Gordon H. Guyatt, Andrew D. Oxman, Regina Kunz, 等. GRADE指南: Ⅶ.证据质量评价——不一致性. 中国循证医学杂志, 2011, 11(12): 1444-1451.
22. Gordon Guyatt, Andrew D. Oxman, Regina Kunz, 等. GRADE指南: Ⅷ.证据质量评价——间接性. 中国循证医学杂志, 2011, 11(12): 1452-1458.
23. Gordon H. Guyatt, Andrew D. Oxman, Shahnaz Sultan, 等, GRADE指南: Ⅸ.证据质量升级. 中国循证医学杂志, 2011, 11(12): 1459-1463.
24. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from.
25. Guyatt GH, Oxman AD, Kunz R, et al . GRADE guidelines: 2. Framing the question and deciding on important outcomes. Clin Epidemiol , 2011, 64(4): 395-400.
26. Schünemann H, Bro?ek J, Oxman A, editors. GRADE handbook for Grading quality of evidence and strength of recommendation. 3.2 [updated March 2009]. Section 3.

Previous Article
Effectiveness and Safety of Sarpogrelate Hydrochloride for Peripheral Arterial Disease: A Systematic Review
Next Article
How to Apply the Results of Systematic Reviews to Clinical Practice

Chinese Journal of Evidence-Based Medicine

Evidence-Based Evaluation and Selection of Essential Medicine for Pilot Township Health Centers Located in Eastern, Central and Western China, Part II: Study on Evaluation Standards, Methods and Processes

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content